Daniel M. Anderson

5.6k total citations · 1 hit paper
34 papers, 1.2k citations indexed

About

Daniel M. Anderson is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Daniel M. Anderson has authored 34 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Genetics and 6 papers in Hematology. Recurrent topics in Daniel M. Anderson's work include Cancer Treatment and Pharmacology (7 papers), Glioma Diagnosis and Treatment (3 papers) and Chemotherapy-related skin toxicity (3 papers). Daniel M. Anderson is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Glioma Diagnosis and Treatment (3 papers) and Chemotherapy-related skin toxicity (3 papers). Daniel M. Anderson collaborates with scholars based in United States, Australia and Singapore. Daniel M. Anderson's co-authors include Charles L. Loprinzi, Stanislav Henkin, Alfonso Tafur, Robert D. McBane, Charles Kuzma, Usha Perepu, Aneel A. Ashrani, Waldemar E. Wysokiński, Charles J. Lenz and Krishna Gundabolu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Daniel M. Anderson

33 papers receiving 1.2k citations

Hit Papers

Apixaban and dalteparin in active malignancy‐associated v... 2019 2026 2021 2023 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial
    2019 375 citations Robert D. McBane, Waldemar E. Wysokiński et al. Journal of Thrombosis and Haemostasis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel M. Anderson United States 15 387 328 326 269 223 34 1.2k
Casey L. O’Connell United States 21 637 1.6× 796 2.4× 423 1.3× 175 0.7× 717 3.2× 85 2.1k
Catherine Lambert Belgium 20 736 1.9× 611 1.9× 605 1.9× 142 0.5× 155 0.7× 98 1.8k
Patrick Van Dreden France 19 543 1.4× 696 2.1× 324 1.0× 145 0.5× 205 0.9× 101 1.4k
Yona Nadir Israel 21 229 0.6× 404 1.2× 122 0.4× 122 0.5× 372 1.7× 66 1.2k
Yun‐Gyoo Lee South Korea 15 95 0.2× 119 0.4× 84 0.3× 436 1.6× 233 1.0× 72 942
Richard A. Drachtman United States 19 53 0.1× 248 0.8× 62 0.2× 217 0.8× 202 0.9× 69 1.1k
Virginia Martínez-Marín Spain 13 167 0.4× 45 0.1× 110 0.3× 210 0.8× 67 0.3× 29 570
R. Junker Germany 15 192 0.5× 363 1.1× 125 0.4× 98 0.4× 97 0.4× 29 828
Manu Varma United States 15 473 1.2× 330 1.0× 367 1.1× 39 0.1× 87 0.4× 19 990
Andrew Will United Kingdom 21 34 0.1× 797 2.4× 93 0.3× 142 0.5× 331 1.5× 53 1.6k

Countries citing papers authored by Daniel M. Anderson

Since Specialization
Citations

This map shows the geographic impact of Daniel M. Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel M. Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel M. Anderson more than expected).

Fields of papers citing papers by Daniel M. Anderson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel M. Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel M. Anderson. The network helps show where Daniel M. Anderson may publish in the future.

Co-authorship network of co-authors of Daniel M. Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel M. Anderson. A scholar is included among the top collaborators of Daniel M. Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel M. Anderson. Daniel M. Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
George, Suzanne, Nancy Campbell, Shauna L. Hillman, et al.. (2024). Feasibility of structuring electronic health record data to facilitate real‐world data research: ICAREdata methods applied to multicenter cancer clinical trials. Cancer. 131(1). e35528–e35528. 5 indexed citations
3.
Seiwert, Tanguy Y., Sara Kochanny, Kevin Wood, et al.. (2020). A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study. Cancer. 126(14). 3237–3243. 15 indexed citations
4.
5.
McBane, Robert D., Waldemar E. Wysokiński, Jennifer Le‐Rademacher, et al.. (2019). Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. Journal of Thrombosis and Haemostasis. 18(2). 411–421. 375 indexed citations breakdown →
6.
Lonial, Sagar, Susanna Jacobus, Rafaël Fonseca, et al.. (2019). Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. Journal of Clinical Oncology. 38(11). 1126–1137. 164 indexed citations
7.
Bekaii‐Saab, Tanios, Fang‐Shu Ou, Daniel M. Anderson, et al.. (2018). Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)–An ACCRU Network study.. Journal of Clinical Oncology. 36(4_suppl). 611–611. 31 indexed citations
8.
Bartlett, Nancy L., Brian A. Costello, Betsy LaPlant, et al.. (2017). Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 131(2). 182–190. 110 indexed citations
9.
Anderson, Daniel M., et al.. (2017). Magnetic Resonance Imaging Characteristics of a Baerveldt Glaucoma Implant. Journal of Glaucoma. 26(6). 534–540. 3 indexed citations
10.
Galanis, Evanthia, S. Keith Anderson, P Anastasiadis, et al.. (2015). NCCTG N0872 (Alliance): A randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM).. Journal of Clinical Oncology. 33(15_suppl). 2004–2004. 5 indexed citations
11.
Park, Haeseong, Rui Qin, Thomas J. Smith, et al.. (2014). North Central Cancer Treatment Group N10C2 (Alliance). Menopause The Journal of The North American Menopause Society. 22(6). 627–632. 17 indexed citations
12.
Anderson, Daniel M., Benjamin Hansen, & Daniel I. Rees. (2012). Medical Marijuana Laws and Teen Marijuana Use. SSRN Electronic Journal. 5 indexed citations
13.
Anderson, Daniel M., et al.. (2010). Distribution and morphology of the juxtapositions between growth hormone-releasing hormone-(ghrh)-immunoreactive neuronal elements. Growth Hormone & IGF Research. 20(5). 356–359. 2 indexed citations
14.
Repanos, Costa, et al.. (2010). Manipulation of nasal fractures with local anaesthetic: A ‘How to do it’ with online video tutorial. Emergency Medicine Australasia. 22(3). 236–239. 2 indexed citations
15.
Anderson, Daniel M.. (2009). Does Information Matter? The Effect of the Meth Project on Meth Use Among Youths. SSRN Electronic Journal. 7 indexed citations
16.
Steensma, David P., Shaker R. Dakhil, Paul J. Novotny, et al.. (2009). A Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week Epoetin Alfa and Every-3-Week Darbepoetin Alfa: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC).. Blood. 114(22). 3008–3008. 2 indexed citations
17.
Anderson, Daniel M., et al.. (2007). Impact of Chemotherapy in Women with Metastatic Breast Cancer Diagnosed 1990-2003. Clinical Breast Cancer. 7(10). 801–803. 1 indexed citations
18.
Wu, Hao, Isabelle Romieu, Juan-Jose Sienra-Monge, et al.. (2007). Genetic variation in S-nitrosoglutathione reductase (GSNOR) and childhood asthma. Journal of Allergy and Clinical Immunology. 120(2). 322–328. 60 indexed citations
19.
Alam, Hasan B., Gemma B. Uy, Dana L. Miller, et al.. (2003). Comparative Analysis of Hemostatic Agents in a Swine Model of Lethal Groin Injury. The Journal of Trauma: Injury, Infection, and Critical Care. 54(6). 1077–1082. 134 indexed citations
20.
Alam, Hasan B., Mark W. Bowyer, Elena Koustova, et al.. (2002). Learning and memory is preserved after induced asanguineous hyperkalemic hypothermic arrest in a swine model of traumatic exsanguination. Surgery. 132(2). 278–288. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Casey L. O’Connell Breakdown of academic impact, for papers by Catherine Lambert Breakdown of academic impact, for papers by Patrick Van Dreden Breakdown of academic impact, for papers by Yona Nadir Breakdown of academic impact, for papers by Yun‐Gyoo Lee Breakdown of academic impact, for papers by Richard A. Drachtman Breakdown of academic impact, for papers by Virginia Martínez-Marín Breakdown of academic impact, for papers by R. Junker Breakdown of academic impact, for papers by Manu Varma Breakdown of academic impact, for papers by Andrew Will
Rankless by CCL
2026